“Considering the shock with the yet unexplained failure of our Phase-3 study with retogatein, which brought a dramatic fall in the company’s share value, times are now exciting, while efforts are ongoing to visualize and use the company’s quite valuable assets in the best possible way,” says Anders Essen-Moller, that since April has taken over the role as CEO of Diamyd Medical.

Cost reduction steps

Whilst implementing several cost reduction steps, the company is structuring its approach for evaluating these opportunities with the aim to maximize value for its shareholders.

Key assets and operations

Key assets and operations of the company are not limited to: a public listing on Nasdaq First North Growth Market, approximately 20,000 shareholders, and ownership of a GMP-approved biomanufacturing facility in Umeå, with capabilities supporting CDMO activities (the company is also engaged in discussions regarding a potential sales of the facility), Retogatein (rhGAD65), a clinical-stage immunotherapy candidate with orphan and fast track designation for Stage 3 type 1 diabetes, patents, and an expected cash position of approximately SEK 225 million at the end of this calendar year, as previously announced.

Reappointed its previous CFO

In addition to the above, Diamyd has reappointed its previous CFO – Anna Styrud – as an interim CFO starting on June 29th, 2026.